<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437307</url>
  </required_header>
  <id_info>
    <org_study_id>3104000</org_study_id>
    <nct_id>NCT00437307</nct_id>
  </id_info>
  <brief_title>Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse</brief_title>
  <acronym>HECTOR</acronym>
  <official_title>Topotecan Plus Carboplatin im Vergleich Zur Standardtherapie (Paclitaxel Plus Carboplatin Oder Gemcitabin Plus Carboplatin) in Der Therapie Von Patientinnen Mit Platin-sensitivem Rezidivierten Epithelialen Ovarialkarzinom, Peritonealkarzinom Oder Tubenkarzinom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Eastern Germany Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Eastern Germany Society of Gynaecologic Oncology</source>
  <brief_summary>
    <textblock>
      Determination of progression free survival after 12 months of FU

      Determination of total survival, response and quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Germany there are two established therapy regimes for platin sensitive ovarian cancer: the
      combination of carboplatin and paclitaxel as well as the combination of carboplatin with
      gemcitabine. Choice of therapy is individual due to missing randomized comparisons between
      the regimes. Topotecan has shown good efficacy in second-line therapy of ovarian cancer as
      well as a good, especially, non-hematoxic toxicity profile. Several phase II-studies have
      demonstrated a synergistic effect of topotecan in combination with carboplatin exhibiting
      good efficacy and tolerability.

      It shall be tested in this randomized phase III-study if the combination of topotecan and
      carboplatin shows improvement of progression-free survival in comparison to the standard
      regimes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>after 1 year-follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival, efficacy and tolerability of the regimes and quality of life</measure>
    <time_frame>during study and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Hycamtin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ≥18 years of age with platinum-sensitive recurrent ovarian cancer occurring at
             least six months after completion of primary standard therapy are eligible

          -  Patients with measurable or assessable lesions or CA-125 ≥ 2x ULN an Eastern
             Co-operative Oncology Group (ECOG) performance status ≤ 2

          -  All patients will provide written informed consent

        Exclusion Criteria:

          -  Patients with more than two chemotherapies in their history

          -  Progress less than six months after completion of primary standard therapy

          -  Simultaneous or planned radiation

          -  Any known hypersensitivity to topotecan, carboplatin, paclitaxel or gemcitabine

          -  Patients with infection

          -  Patients who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli</last_name>
    <role>Study Chair</role>
    <affiliation>Charité Campus Vichow Klinikum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

